Latest news with #AXIOS
Ya Libnan
12 hours ago
- Politics
- Ya Libnan
Trump still pursuing diplomacy with Iran, will make a decision ‘within 2 weeks on whether to join Israel'
Trump still pursuing diplomacy with Iran, will make a decision 'within two weeks' on whether to join Israel' President Trump will make a decision 'within two weeks' on whether to join Israel's war against Iran to eliminate its nuclear program, White House press secretary Karoline Leavitt told reporters on Thursday. Citing the 'chance for substantial negotiations' with Iran, Trump is leaving the door open to a diplomatic solution in the coming days that could avert a major escalation in the Middle East. Trump met with his top national security team in the Situation Room on Thursday — the third such meeting in three days. He's seriously considering joining the war, but wants to ensure three things are true, U.S. officials say: 'I have a message directly from the president: 'Based on the fact that there is a chance for substantial negotiations that may or may not take place with Iran in the near future, I will make my decision on whether or not to go within the next two weeks,'' Leavitt said at Thursday's White House briefing. As Trump has deliberated in recent days over whether to join the war, special envoy Steve Witkoff has maintained direct communication with Iranian Foreign Minister Abbas Araghchi, as Axios reported Wednesday. The foreign ministers of France, Germany and the U.K., along with the European Union's foreign policy chief, are set to meet with Araghchi in Geneva on Friday, a source with knowledge of the situation said. AXIOS
Yahoo
13-06-2025
- Business
- Yahoo
BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?
Boston Scientific's BSX Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) conditions using innovative, less invasive technologies. The company is strategically positioned to benefit from the expanding global endoscopy devices market through its strong innovation pipeline and well-diversified product offerings. Per an Allied Market Research report, the global endoscopy devices market was valued at $28.1 billion in 2022 and is projected to reach $44.1 billion by 2032 at a CAGR of 4.6% from 2023 to 2032. Sales of Endoscopy products totaled $673 million, up 6% both operationally and organically, for the first quarter of 2025. Endoscopy sales accounted for 14% of the company's overall revenues. Sales growth can be attributed to steady performance across geographies and BSX's diverse product suite. A key highlight was the continued double-digit growth of the AXIOS Stent and Electrocautery Enhanced Delivery System. AXIOS is the first and only stent indicated for transgastric or transduodenal endoscopic drainage of symptomatic pancreatic pseudocysts. Additionally, the Endoluminal Surgery franchise saw double-digit growth from two innovative technologies — OverStitch and MANTIS Clip. This indicates robust adoption of advanced endoscopic tools aimed at minimally invasive procedures. The segment's consistent growth is attributed to its balanced regional performance and strong traction in newer, high-potential product lines. Accordingly, Boston Scientific is poised to sustain long-term growth in the high-potential endoscopy space. Stryker's SYK Endoscopy segment posted strong growth in the first quarter, with U.S. organic sales rising 11.1%, driven by double-digit gains in core endoscopy and sports medicine portfolios. Key growth catalysts included the 1788 camera platform, as it continues to win customers. Robust global performance and product innovation position the segment for continued success. Johnson & Johnson JNJ, through its subsidiary Ethicon, is a key player in the field of endoscopy. The company offers advanced energy-based endoscopic surgery platforms known as ENDOPATH and HARMONIC. Additionally, it provides staplers and suturing devices such as ECHELON and PROXISURE. JNJ's strategic growth initiatives involve a strong emphasis on digital surgery platforms, artificial intelligence and analytics to enhance endoscopic procedures. Shares of Boston Scientific have gained 27.3% in the past year compared with the industry's growth of 9.7%. The S&P 500 composite has also grown 11% in the same period. Image Source: Zacks Investment Research From a valuation standpoint, BSX trades at a forward 12-month price-to-earnings ratio (P/E) of 32.13X, above the industry's 21.33X. Image Source: Zacks Investment Research The Zacks Consensus Estimate for BSX's earnings has been on the rise over the past 60 days. Image Source: Zacks Investment Research BSX stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Stryker Corporation (SYK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Ya Libnan
26-05-2025
- Politics
- Ya Libnan
Israel is losing almost all its allies as it forges on in Gaza
Many of Israel's closest international allies have broken publicly with Prime Minister Benjamin Netanyahu's government for its relentless pummeling of Gaza and freezing of desperately needed humanitarian aid. Why it matters: Netanyahu had unprecedented international legitimacy to fight back against Hamas after the Oct. 7 attacks. But a gradual decline in support as the war dragged on has now turned into a diplomatic tsunami. Driving the news: Netanyahu lost many of his remaining friends in the West, outside of the U.S., over the last two months after terminating a ceasefire in March and blocking all deliveries of food, water and medicine to Gaza. What they're saying: 'We will not stand by while the Netanyahu Government pursues these egregious actions. If Israel does not cease the renewed military offensive and lift its restrictions on humanitarian aid, we will take further concrete actions in response,' President Emmanuel Macron of France, Prime Minister Mark Carney of Canada and Prime Minister Keir Starmer of the U.K. said in a joint statement on May 19. State of play: Israel's isolation is moving beyond mere rhetoric. The other side: Netanyahu and his government have responded to the criticism by accusing European leaders of antisemitism and claiming they're caving to pressure from the Muslim minorities in their countries. But Israel also agreed to allow some aid into Gaza for the first time since March. Behind the scenes: In a series of Security Council meetings back in March, Foreign Minister Gideon Sa'ar warned Netanyahu that suspending humanitarian aid would not weaken Hamas, but would drive away Israel's allies. What to watch: While Trump seems to have cooled on his own plan to expel all 2 million Palestinians from Gaza to build a new 'riviera,' Netanyahu said last week for the first time that the war won't end until that plan is implemented. AXIOS
